Cargando…

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis

Background and objective: Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-quality care. Belgium is a country known to have low bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandenplas, Yannick, Simoens, Steven, Van Wilder, Philippe, Vulto, Arnold G., Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091126/ https://www.ncbi.nlm.nih.gov/pubmed/33953678 http://dx.doi.org/10.3389/fphar.2021.644187

Ejemplares similares

Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
por: Vandenplas, Yannick, et al.
Publicado: (2023)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
por: Barbier, Liese, et al.
Publicado: (2021)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
por: Wilder, Philippe Van
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
por: Vandenplas, Yannick, et al.
Publicado: (2022)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
por: Barcina Lacosta, Teresa, et al.
Publicado: (2023)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
por: Barbier, Liese, et al.
Publicado: (2022)

How to select a best-value biological medicine? A practical model to support hospital pharmacists
por: Barbier, Liese, et al.
Publicado: (2022)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Not one, but many: developing a multi-indication pricing model for medicines in Belgium
por: Maes, Ingrid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1eojn4k0phrol2vcr3ok9fo7m2